Apmonia Therapeutics

📍 Reims, France🗓 Founded 2019👥 20 employees💰 Last funded Jun 2026
Biotechnology🌐 apmonia-therapeutics.com
Website LinkedIn
Apmonia Therapeutics is a clinical-stage biotechnology company developing innovative peptide therapeutics designed to target the tumor microenvironment and improve outcomes for patients with solid tumors. Our approach focuses on overcoming one of oncology’s greatest challenges: the tumor microenvironment, a protective ecosystem that drives tumor growth, immune escape, and treatment resistance. Our lead candidate, TAX2, is a first-in-class peptide modulator of the TSP-1/CD47 pathway. Following strong preclinical results and CTA approval in Europe, TAX2 is entering Phase 1/2a clinical development in advanced solid tumors.
1
Total investors
0
Early stage
0
Mid stage
1
Late stage
2019
Founded

Investors

1 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
France
1
Frequently asked questions
Who invested in Apmonia Therapeutics?
Apmonia Therapeutics has 1 investors on record on gritt.io and 1 late-stage investors.
When did Apmonia Therapeutics last raise funding?
The most recent investment in Apmonia Therapeutics recorded on gritt.io was in June 2026.
When was Apmonia Therapeutics founded?
Apmonia Therapeutics was founded in 2019.
What industry is Apmonia Therapeutics in?
Apmonia Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Apmonia Therapeutics based?
Apmonia Therapeutics is headquartered in Reims, France.